Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  MUMBAI STOCK EXCHANGE  >  Lupin Limited    500257   INE326A01037

LUPIN LIMITED

(500257)
  Report
End-of-day quote. End-of-day quote MUMBAI STOCK EXCHANGE - 01/25
1081.85 INR   +0.21%
01/25LUPIN : Gets US FDA Approval for Chronic Kidney Disease Drug
MT
01/07LUPIN : Gets US FDA Approval for Diabetes Control Drug
MT
01/06LUPIN : Gets US FDA Approval for Bacterial Infection Treatment Drug
MT
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Mumbai Stock Exchange
01/19/2021 01/20/2021 01/21/2021 01/22/2021 01/25/2021 Date
1090.15 1087.45 1068.35 1079.55 1081.85 Last
97090 72487 75906 138073 249783 Volume
+2.54% -0.25% -1.76% +1.05% +0.21% Change
Financials
Sales 2021 157 B 2 163 M 2 163 M
Net income 2021 10 384 M 143 M 143 M
Net Debt 2021 15 410 M 212 M 212 M
P/E ratio 2021 47,1x
Yield 2021 0,54%
Sales 2022 179 B 2 455 M 2 455 M
Net income 2022 16 669 M 229 M 229 M
Net Debt 2022 5 957 M 81,8 M 81,8 M
P/E ratio 2022 29,3x
Yield 2022 0,69%
Capitalization 491 B 6 729 M 6 739 M
EV / Sales 2021 3,21x
EV / Sales 2022 2,78x
Nbr of Employees 18 302
Free-Float 51,3%
More Financials
Company
Lupin Limited is a leading Indian pharmaceutical group. Its products are used to treat tuberculosis, diabetes, asthma, cardiovascular diseases, infections, etc. The group's activity is organized around 2 areas: - design and production of generic and brand-name formulations; - production of active pharmaceutical ingredients. At the end of March 2020, the group had 15 production sites India (12), the United States,... 
Sector
Pharmaceuticals
Calendar
01/28Earnings Release
More about the company
Notations Surperformance© of Lupin Limited
Trading Rating : Investor Rating :
More Ratings
All news about LUPIN LIMITED
01/25LUPIN : Gets US FDA Approval for Chronic Kidney Disease Drug
MT
01/07LUPIN : Gets US FDA Approval for Diabetes Control Drug
MT
01/06LUPIN : Gets US FDA Approval for Bacterial Infection Treatment Drug
MT
2020LUPIN : Launches Generic Drug for Post-Organ Transplant Procedures Following US ..
MT
2020LUPIN : Launches Meloxicam Capsules
MT
2020LUPIN : Gets US FDA Nod to Market Efinaconazole Topical Solution
MT
2020Indian Indices Lock Gains on Tuesday; Lupin Rises 3%
MT
2020Lupin Gets US FDA Approval for Rufinamide Oral Suspension
MT
2020Lupin Gets US FDA Approval for Colesevelam Hydrochloride Tablets
MT
2020Indian Stocks Lock Gains on Thursday's Closing; ABB India Climbs 3%
MT
2020LUPIN : Shares Rise on Settlement of Dispute with Sellers of US-based GAVIS
MT
2020PRESS RELEASE : Scottish Medicines Consortium approves Lupin's NaMuscla(R) (mexi..
DJ
2020Scottish Medicines Consortium approves Lupin's NaMuscla® (mexiletine) to trea..
GL
2020Lupin Gets US FDA Approval to Market Wilson's Disease Drug Penicillamine
MT
2020Indian Indices Ride High Wave on Tuesday; Aurobindo Pharma Up 3%
MT
More news
News in other languages on LUPIN LIMITED
2020LUPIN LIMITED : Veröffentlichung des Jahresergebnisses
2020LUPIN LIMITED : publication des résultats annuels
2019WALL STREET STOCK EXCHANGE : Repli en vue à Wall Street, le commerce USA-UE inqu..
2017LUPIN LIMITED : Veröffentlichung des Jahresergebnisses
2017LUPIN LIMITED : publication des résultats annuels
More news
Analyst Recommendations on LUPIN LIMITED
More recommendations
Chart LUPIN LIMITED
Duration : Period :
Lupin Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LUPIN LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 32
Average target price 1 002,03 INR
Last Close Price 1 081,85 INR
Spread / Highest target 12,2%
Spread / Average Target -7,38%
Spread / Lowest Target -33,0%
EPS Revisions
Managers and Directors
NameTitle
Vinita D. Gupta Chief Executive Officer & Executive Director
Manju Deshbandhu Gupta Non-Executive Chairman
Ramesh Swaminathan CFO, Executive Director & Head-Corporate Affairs
Alok Sonig CEO-US Generics, Global Head-R&D
Dhananjay Bakhle Executive Vice President-Medical Research
Sector and Competitors
1st jan.Capitalization (M$)
LUPIN LIMITED10.77%6 729
JOHNSON & JOHNSON8.32%436 949
ROCHE HOLDING AG3.82%309 894
NOVARTIS AG2.96%220 401
PFIZER INC.1.36%207 217
MERCK & CO., INC.-0.79%205 312